Skip to main content
U.S. flag

An official website of the United States government

Here’s how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

RxNorm January 2022 Release

RxNorm January 2022 Release. NLM Tech Bull. 2022 Jan-Feb;(444):b1.

January 03, 2022 [posted]

The RxNorm January monthly release became available for download on Monday, January 3, 2022 and contains three COVID-19 related medications: Evusheld, Paxlovid, and molnupiravir. 

RXNORM DATA CHANGES

Added Evusheld, Paxlovid & molnupiravir COVID-19 Related Medications 

The FDA recently issued Emergency Use Authorization (EUA) for AstraZeneca’s Evusheld, Pfizer's Paxlovid, and Merck's molnupiravir, and they are included in the RxNorm January 2022 monthly releases.

Evusheld is a prophylactic medication for COVID-19 for certain adults and pediatric individuals and it contains the antibodies tixagevimab co-packaged with cilgavimab, which are administered together. Paxlovid and molnupiravir are oral pills that treat COVID-19 disease. Both can be used in adults. Paxlovid can also be used in certain children over 12 years of age.

Here are the new COVID-19 related concepts in RxNorm:

RXCUI TTY RxNorm Name
2587313 BPCK {1 (1.5 ML cilgavimab 100 MG/ML Injection) / 1 (1.5 ML tixagevimab 100 MG/ML Injection) } Pack [Evusheld 2 vial carton]
2587312 GPCK {1 (1.5 ML cilgavimab 100 MG/ML Injection) / 1 (1.5 ML tixagevimab 100 MG/ML Injection) } Pack
2587899 BPCK {20 (nirmatrelvir 150 MG Oral Tablet) / 10 (ritonavir 100 MG Oral Tablet) } Pack [Paxlovid 5-Day]
2587898 GPCK {20 (nirmatrelvir 150 MG Oral Tablet) / 10 (ritonavir 100 MG Oral Tablet) } Pack
2587906 SCD molnupiravir 200 MG Oral Capsule